Atypical antipsychotics in bipolar disorder: systematic review of randomised trials

Derry, Sheena; Moore, R. Andrew
January 2007
BMC Psychiatry;2007, Vol. 7, p40
Academic Journal
Background: Atypical antipsychotics are increasingly used for treatment of mental illnesses like schizophrenia and bipolar disorder, and considered to have fewer extrapyramidal effects than older antipsychotics. Methods: We examined efficacy in randomised trials of bipolar disorder where the presenting episode was either depression, or manic/mixed, comparing atypical antipsychotic with placebo or active comparator, examined withdrawals for any cause, or due to lack of efficacy or adverse events, and combined all phases for adverse event analysis. Studies were found through systematic search (PubMed, EMBASE, Cochrane Library), and data combined for analysis where there was clinical homogeneity, with especial reference to trial duration. Results: In five trials (2,206 patients) participants presented with a depressive episode, and in 25 trials (6,174 patients) the presenting episode was manic or mixed. In 8-week studies presenting with depression, quetiapine and olanzapine produced significantly better rates of response and symptomatic remission than placebo, with NNTs of 5-6, but more adverse event withdrawals (NNH 12). With mania or mixed presentation atypical antipsychotics produced significantly better rates of response and symptomatic remission than placebo, with NNTs of about 5 up to six weeks, and 4 at 6-12 weeks, but more adverse event withdrawals (NNH of about 22) in studies of 6-12 weeks. In comparisons with established treatments, atypical antipsychotics had similar efficacy, but significantly fewer adverse event withdrawals (NNT to prevent one withdrawal about 10). In maintenance trials atypical antipsychotics had significantly fewer relapses to depression or mania than placebo or active comparator. In placebo-controlled trials, atypical antipsychotics were associated with higher rates of weight gain of ≥7% (mainly olanzapine trials), somnolence, and extrapyramidal symptoms. In active controlled trials, atypical antipsychotics were associated with lower rates of extrapyramidal symptoms, but higher rates of weight gain and somnolence. Conclusion: Atypical antipsychotics are effective in treating both phases of bipolar disorder compared with placebo, and as effective as established drug therapies. Atypical antipsychotics produce fewer extrapyramidal symptoms, but weight gain is more common (with olanzapine). There is insufficient data confidently to distinguish between different atypical antipsychotics.


Related Articles

  • Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Souza, F. G. M.; Goodwin, G. M.; Souza, F G // British Journal of Psychiatry;May91, Vol. 158, p666 

    Meta-analysis was used to establish the efficacy of lithium in acute treatment and prophylaxis of depressive illness from existing published clinical trials. Effect sizes were measured by the odds ratio using the Mantel-Haenszel method and the Pearson product-moment correlation coefficient. Some...

  • Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial. Akhondzadeh, Shahin; Mohajari, Hassan; Mohammadi, Mohammad Reza; Amini, Homayoun // BMC Psychiatry;2003, Vol. 3, p7 

    Background: Bipolar disorder is a lifelong episodic condition characterized by mood swings between mania and depression. Several lines of evidence suggest that serotonin is likely to play a pivotal role in the pathophysiology of bipolar disorder. Ritanserin, a 5-HT2 receptor antagonist, has been...

  • Pediatric and Adolescent Psychiatry.  // Current Medical Literature: Psychiatry;2006, Vol. 17 Issue 4, p133 

    The article offers observation on the study "A Double-Blind, Randomized, Placebo-Controlled Trial of Oxcarbazepine in the Treatment of Bipolar Disorder in Children and Adolescents," by K. D. Wagner in a 2006 issue of the "American Journal of Psychiatry." It points out the limitations of the...

  • Lovastatin as an Adjuvant to Lithium for Treating Manic Phase of Bipolar Disorder: A 4-Week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Ghanizadeh, Ahmad; OmraniSigaroodi, Motahhar; Javadpour, Ali; Dabbaghmanesh, Mohammad Hossein; Shafiee, Sara // Depression Research & Treatment;2014, p1 

    Objectives. Many patients with bipolar disorder suffer from metabolic disorder. Lovastatin is effective for treating major depression. This double-blind randomized placebo controlled clinical trial investigates whether lovastatin is a useful adjuvant to lithium for treating mania. Methods....

  • The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials -- A secondary analysis. Walach, Harald; Sadaghiani, Catarina; Dehm, Cornelia; Bierman, Dick // BMC Medical Research Methodology;2005, Vol. 5, p26 

    Background and purpose: Placebo response rates in clinical trials vary considerably and are observed frequently. For new drugs it can be difficult to prove effectiveness superior to placebo. It is unclear what contributes to improvement in the placebo groups. We wanted to clarify, what elements...

  • Novel study designs to investigate the placebo response. Enck, Paul; Klosterhalfen, Sibylle; Zipfel, Stephan // BMC Medical Research Methodology;2011, Vol. 11 Issue 1, p90 

    Background: Investigating the size and mechanisms of the placebo response in clinical trials have relied on experimental procedures that simulate the double-blind randomized placebo-controlled design. However, as the conventional design is thought to elucidate drug rather than placebo actions,...

  • A New Approach to the Treatment of Uncomplicated Cystitis: Results of a Randomized Placebo-Controlled Clinical Trial. Salvatorelli, Nicola; García-Larrosa, alejandro; allegrini, alessandro; Pavone, Daniele // Urologia Internationalis;Oct2016, Vol. 97 Issue 3, p347 

    Objective: To assess the efficacy and safety of a new medical device (MD; a capsule whose main component is a crosslinked protein) in the prevention of uncomplicated cystitis recurrences. Methods: Adult women with acute cystitis symptoms and a ciprofloxacin-susceptible isolate in urine culture...

  • Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. Chu, Jennifer; Sloan, Caroline E.; Freedberg, Kenneth A.; Yazdanpanah, Yazdan; Losina, Elena // AIDS Research & Therapy;2011, Vol. 8, p14 

    Background: Our goal was to illustrate a method for making indirect treatment comparisons in the absence of head-to-head trials, by portraying the derivation of published efficacies for prophylaxis regimens of HIV-related opportunistic infections. Results: We identified published results of...

  • QRXPHARMA BEGINS PHASE III CLINICAL TRIAL FOR PAIN THERAPY.  // Worldwide Biotech;Jan2008, Vol. 20 Issue 1, p1 

    The article reports on the Phase III clinical trial conducted by QRxPharma for its lead product candidate Q8003IR, an immediate release dual-opioid pain therapy. The trial involved a double-blind, placebo-controlled study that aims to compare the efficacy and safety of four different dosage...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics